Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis

American Journal of Transplantation

Volumn 3, Issue 6, 2003, Pages 731-735

  Akalin, Enver ^a   Sehgal, Vinita ^a   Ames, Scott ^a   Hossain, Sabera ^a   Daly, Lisa ^a   Barbara, Murphy ^a   Bromberg, Jonathan S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Thymoglobulin; Transplantation; Valganciclovir

Indexed keywords

ANTIULCER AGENT; BASILIXIMAB; CALCIUM; CLOTRIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GASTRITIS; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION;

EID: 0037531594     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00140.x     Document Type: Article

References (20)

1. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 848-855.
2. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002; 39: 1088-1095.
3. Siu CWD, Chan TM, Li FK et al. Association between antithymocyte globulin administration and cytomegalic virus infection and/or disease in cadaveric renal allograft recipients. Transplant Proc 2000; 32: 1932-1934.
4. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental mycophenolate mofetil renal transplantation Study Group. Transplantation 1998; 65: 1450-1454.
5. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on CMV disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325-330.
6. Flechner SM, Avery RK, Fisher R et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66: 1682-1688.
7. Lowance D, Neumayer H, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470.
8. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721-729.
9. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846.
10. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 1174-1180.
11. Kaufman DB, Leventhal JR, Gallon LG et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001; 72: 1940-1945.
12. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
13. Martin DF, Siera-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retnitis. N Engl J Med 2002; 346: 1119-1126.
14. Czock D, Scholle C, Rasche FM, Schaarschmidt, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-150.
15. Paya CV. A randomized, double-blind, double dummy, active comparator controlled multi-center study of the efficacy and safety of valganciclovir vs oral ganciclovir for prevention of CMV disease in 372 high-risk (D+/R-) heart, liver, and kidney recipients. Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002: San Diego, CA (Abstract).
16. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
17. Lurain NS, Bhorade SM, Pursell KJ et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760-768.
18. Hart GD, Paya CV. Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73-81.
19. Emery VC. Prophylaxis for CMV should not now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-86.
20. Humar A, Uknis M, Carlone-Jambor C et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94-97.